Phlow
Phlow Corp. is a U.S.-based public benefit corporation dedicated to reimagining essential medicines through innovative manufacturing processes, including flow chemistry, to provide affordable, high-quality, and domestically produced medicines. The company aims to strengthen the U.S. pharmaceutical supply chain, reduce dependency on foreign manufacturing, and ensure access to critical medicines for Americans.
Industries
Nr. of Employees
medium (51-250)
Phlow
Products
Onshore API production and finished pharmaceutical products
Production of essential small-molecule APIs and finished dosage forms manufactured in U.S. facilities to supply clinical and commercial demand.
Metric Ton-Scale cGMP Facility
A purpose-built large-volume production facility delivering 50-100 metric tons annually using advanced batch and continuous manufacturing modes with dual independent process trains.
CDMO Services
Contract development and manufacturing organization (CDMO) services provided by Phlow for pharmaceutical development and manufacturing.
Strategic Active Pharmaceutical Ingredient Reserve (SAPIR®)
A strategic inventory of critical and essential ingredients that can be converted rapidly to finished drug products in case of emergency, maintaining a reserve of long shelf-life precursor chemicals and APIs on U.S. soil.
SAPIR®
Strategic Active Pharmaceutical Ingredient Reserve program for essential medicines and medical countermeasures.
P-00013-AT
Formulation-ready small molecule API developed with advanced technologies for essential medicines.
Onshore API production and finished pharmaceutical products
Production of essential small-molecule APIs and finished dosage forms manufactured in U.S. facilities to supply clinical and commercial demand.
Metric Ton-Scale cGMP Facility
A purpose-built large-volume production facility delivering 50-100 metric tons annually using advanced batch and continuous manufacturing modes with dual independent process trains.
CDMO Services
Contract development and manufacturing organization (CDMO) services provided by Phlow for pharmaceutical development and manufacturing.
Strategic Active Pharmaceutical Ingredient Reserve (SAPIR®)
A strategic inventory of critical and essential ingredients that can be converted rapidly to finished drug products in case of emergency, maintaining a reserve of long shelf-life precursor chemicals and APIs on U.S. soil.
SAPIR®
Strategic Active Pharmaceutical Ingredient Reserve program for essential medicines and medical countermeasures.
P-00013-AT
Formulation-ready small molecule API developed with advanced technologies for essential medicines.
Services
Contract development and manufacturing of active pharmaceutical ingredients and finished pharmaceutical products at U.S.-based facilities for government and commercial customers.
Laboratory analytical testing, process analytical technology development, and AI-enabled data analysis to support manufacturing quality and process optimization.
Support for technology transfer from R&D to manufacturing, post-transfer verification, method validation, and preparation for regulatory submissions aligned with pharmacopeial standards.
Operational management of a strategic domestic API reserve and ability to ramp production to meet surge demand for essential medicines and medical countermeasures.
Contract development and manufacturing of active pharmaceutical ingredients and finished pharmaceutical products at U.S.-based facilities for government and commercial customers.
Laboratory analytical testing, process analytical technology development, and AI-enabled data analysis to support manufacturing quality and process optimization.
Support for technology transfer from R&D to manufacturing, post-transfer verification, method validation, and preparation for regulatory submissions aligned with pharmacopeial standards.
Operational management of a strategic domestic API reserve and ability to ramp production to meet surge demand for essential medicines and medical countermeasures.
Expertise Areas
- Advanced continuous-flow pharmaceutical manufacturing
- Small-molecule API synthesis and scale-up
- Finished dosage formulation and production
- Analytical method development and laboratory testing
Key Technologies
- Flow chemistry / continuous manufacturing
- Green chemistry process design
- AI-driven analytical systems
- Laboratory-based analytical testing and process analytics
News & Updates
Phlow was recognized as a Crisis Innovator at the Inno on Fire awards, celebrating its efforts in pharmaceutical manufacturing and supply chain resilience.
Phlow announced over $35 million in Series B funding to improve the U.S. medicine supply chain.
Phlow expands its analytical capabilities and adopts AI-driven systems to modernize medicine manufacturing in America.
Phlow achieved a key milestone toward full American-made epinephrine production, validating a cost-competitive process.
Phlow secured a $354 million contract to manufacture medicines for Covid-19, aiming to boost domestic drug production.
Dr. Eric Edwards, CEO of Phlow, discusses the $354 million contract to produce Covid-19 medications.
Phlow was recognized as a Crisis Innovator at the Inno on Fire awards, celebrating its efforts in pharmaceutical manufacturing and supply chain resilience.
Phlow announced over $35 million in Series B funding to improve the U.S. medicine supply chain.
Phlow expands its analytical capabilities and adopts AI-driven systems to modernize medicine manufacturing in America.
Phlow achieved a key milestone toward full American-made epinephrine production, validating a cost-competitive process.
Phlow secured a $354 million contract to manufacture medicines for Covid-19, aiming to boost domestic drug production.
Dr. Eric Edwards, CEO of Phlow, discusses the $354 million contract to produce Covid-19 medications.